Ewha Med J.  2024 Apr;47(2):e17. 10.12771/emj.2024.e17.

Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review

• Joo SK
• Kim W

• KMID: 2556306
• DOI: http://doi.org/10.12771/emj.2024.e17

Abstract

Understanding the effects of sex and sex differences on liver health and disease is crucial for individualized healthcare and informed decision-making for patients with liver disease. The impact of sex on liver disease varies according to its etiology. Women have a lower prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) than men. However, postmenopausal women face a higher risk of advanced liver fibrosis due to hormonal influences. Sex differences affect the pathogenesis of MASLD, which involves a complex process involving several factors such as hormones, obesity, and the gut microbiome. Furthermore, sex-related differences in the development of MASLDrelated hepatocellular carcinoma have been observed. The sex-specific characteristics of MASLD necessitate an individualized management approach based on scientific evidence. However, research in this area has been lacking. This article reviews the current understanding of sex differences in MASLD.

Keyword

Gastrointestinal microbiome; Hepatocellular carcinoma; Liver cirrhosis; Postmenopause; Sex characteristics

Reference

References

1. Kim N. Sex/gender-specific medicine in the gastrointestinal diseases. Singapore: Springer;2022. DOI: 10.1007/978-981-19-0120-1.

2. Kim N. Sex/gender-specific medicine in clinical areas. Singapore: Springer Nature;2024.

3. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018; 15(1):11–20. DOI: 10.1038/nrgastro.2017.109. PMID: 28930295.

4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1):73–84. DOI: 10.1002/hep.28431. PMID: 26707365.

5. Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology. 2016; 64(1):19–22. DOI: 10.1002/hep.28524. PMID: 26926530.

6. Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019; 70(4):1457–1469. DOI: 10.1002/hep.30626. PMID: 30924946. PMCID: PMC6766425.

7. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006; 21(1):138–143. DOI: 10.1111/j.1440-1746.2005.04086.x. PMID: 16706825.

8. Wong VWS, Chu WCW, Wong GLH, Chan RSM, Chim AML, Ong A, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012; 61(3):409–415. DOI: 10.1136/gutjnl-2011-300342. PMID: 21846782.

9. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012; 47(5):586–595. DOI: 10.1007/s00535-012-0533-z. PMID: 22328022.

10. Wang Z, Xu M, Hu Z, Hultström M, Lai E. Sex-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. Eur J Gastroenterol Hepatol. 2014; 26(9):1015–1021. DOI: 10.1097/MEG.0000000000000151. PMID: 25003744.

11. Long MT, Pedley A, Massaro JM, Hoffmann U, Ma J, Loomba R, et al. A simple clinical model predicts incident hepatic steatosis in a community-based cohort: the Framingham Heart Study. Liver Int. 2018; 38(8):1495–1503. DOI: 10.1111/liv.13709. PMID: 29377504. PMCID: PMC6206437.

12. Balakrishnan M, Patel P, Dunn-Valadez S, Dao C, Khan V, Ali H, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021; 19(1):61:–71.E15. DOI: 10.1016/j.cgh.2020.04.067. PMID: 32360810. PMCID: PMC8796200.

13. Kim W. Epidemiologic landscape of nonalcoholic fatty liver disease is changed during lifetime by menstrual and reproductive status and sex hormonal factors. Clin Gastroenterol Hepatol. 2021; 19(6):1114–1116. DOI: 10.1016/j.cgh.2020.10.054. PMID: 33157317.

14. Yuan L, Kardashian A, Sarkar M. NAFLD in women: unique pathways, biomarkers, and therapeutic opportunities. Curr Hepatol Rep. 2019; 18(4):425–432. DOI: 10.1007/s11901-019-00495-9. PMID: 32523869. PMCID: PMC7286566.

15. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002; 122(6):1649–1657. DOI: 10.1053/gast.2002.33573. PMID: 12016429.

16. Morán-Costoya A, Proenza AM, Gianotti M, Lladó I, Valle A. Sex differences in nonalcoholic fatty liver disease: estrogen influence on the liver-adipose tissue crosstalk. Antioxid Redox Signal. 2021; 35(9):753–774. DOI: 10.1089/ars.2021.0044. PMID: 33736456.

17. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008; 32(6):949–958. DOI: 10.1038/ijo.2008.25. PMID: 18332882. PMCID: PMC2748330.

18. Link JC, Reue K. Genetic basis for sex differences in obesity and lipid metabolism. Annu Rev Nutr. 2017; 37:225–245. DOI: 10.1146/annurev-nutr-071816-064827. PMID: 28628359. PMCID: PMC5759759.

19. Buzzetti E, Parikh PM, Gerussi A, Tsochatzis E. Gender differences in liver disease and the drug-dose gender gap. Pharmacol Res. 2017; 120:97–108. DOI: 10.1016/j.phrs.2017.03.014. PMID: 28336373.

20. Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017; 34(6):1291–1326. DOI: 10.1007/s12325-017-0556-1. PMID: 28526997. PMCID: PMC5487879.

21. Sharpton SR, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin Gastroenterol Hepatol. 2019; 17(2):296–306. DOI: 10.1016/j.cgh.2018.08.065. PMID: 30196156. PMCID: PMC6314895.

22. Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 2017; 152(7):1679–1694.E3. DOI: 10.1053/j.gastro.2017.01.055. PMID: 28214524.

23. Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol. 2012; 9(10):577–589. DOI: 10.1038/nrgastro.2012.156. PMID: 22945443.

24. Balmer ML, Slack E, de Gottardi A, Lawson MAE, Hapfelmeier S, Miele L, et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med. 2014; 6(237):237ra66. DOI: 10.1126/scitranslmed.3008618. PMID: 24848256.

25. Lang S, Schnabl B. Microbiota and fatty liver disease: the known, the unknown, and the future. Cell Host Microbe. 2020; 28(2):233–244. DOI: 10.1016/j.chom.2020.07.007. PMID: 32791115. PMCID: PMC7467841.

26. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017; 65(1):350–362. DOI: 10.1002/hep.28709. PMID: 27358174. PMCID: PMC5191969.

27. Osadchiy V, Martin CR, Mayer EA. The gut–brain axis and the microbiome: mechanisms and clinical implications. Clin Gastroenterol Hepatol. 2019; 17(2):322–332. DOI: 10.1016/j.cgh.2018.10.002. PMID: 30292888. PMCID: PMC6999848.

28. Santos-Marcos JA, Rangel-Zuñiga OA, Jimenez-Lucena R, Quintana-Navarro GM, Garcia-Carpintero S, Malagon MM, et al. Influence of gender and menopausal status on gut microbiota. Maturitas. 2018; 116:43–53. DOI: 10.1016/j.maturitas.2018.07.008. PMID: 30244778.

29. Haro C, Rangel-Zúñiga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P, Delgado-Lista J, et al. Intestinal microbiota is influenced by gender and body mass index. PLoS ONE. 2016; 11(5):e0154090. DOI: 10.1371/journal.pone.0154090. PMID: 27228093. PMCID: PMC4881937.

30. Jašarević E, Morrison KE, Bale TL. Sex differences in the gut microbiome–brain axis across the lifespan. Philos Trans R Soc Lond B Biol Sci. 2016; 371(1688):20150122. DOI: 10.1098/rstb.2015.0122. PMID: 26833840. PMCID: PMC4785905.

31. Villa E. Role of estrogen in liver cancer. Womens Health. 2008; 4(1):41–50. DOI: 10.2217/17455057.4.1.41. PMID: 19072450.

32. Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010; 51(6):1972–1978. DOI: 10.1002/hep.23527. PMID: 20209604.

33. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018; 155(2):443–457.E17. DOI: 10.1053/j.gastro.2018.04.034. PMID: 29733831.

34. Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, Lenz HJ, et al. Impact of sex on the survival of patients with hepatocellular carcinoma: a surveillance, epidemiology, and end results analysis. Cancer. 2014; 120(23):3707–3716. DOI: 10.1002/cncr.28912. PMID: 25081299. PMCID: PMC9191612.

35. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9(5):428–433. DOI: 10.1016/j.cgh.2011.01.023. PMID: 21320639.